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Abstract
Objective—We have previously characterized the reproductive hormone profile in infertile 
women with diminished ovarian reserve (DOR) as being distinct from that seen in age comparable 
healthy controls. Hypothesizing that DOR reflects accelerated reproductive aging, we herein 
compare urinary reproductive hormone dynamics between young women with DOR and a 
population of chronologically older perimenopausal controls.
Methods—In this prospective observational study, urinary levels of pituitary gonadotropins (FSH 
and LH) and metabolites of estrogen (E1c) and progesterone (Pdg) were assessed in daily morning 
urine samples collected in a spontaneous menstrual cycle in 8 infertile premenopausal women with 
DOR and in 11 perimenopausal controls. Areas under the curves (AUC) were calculated for the 
respective measured hormones, and comparisons were made using Mann-Whitney U test.
Results—Urinary E1c levels were significantly attenuated in premenopausal women with DOR 
compared to the older perimenopausal cohort. Despite the relatively lower estrogen, a significantly 
more pronounced LH surge was evident in the younger population. Early follicular FSH was lower 
in the women with DOR, but luteal urinary Pdg excretion was comparable in the two groups.
Conclusion—Our data suggest distinctions in functioning of the central (hypothalamic-pituitary) 
and peripheral (ovarian) components of the hypothalamic-pituitary-ovarian axis in premenopausal 
women with DOR compared to chronologically older perimenopausal controls. Increased 
hypothalamic-pituitary sensitivity to estrogen positive feedback is suggested in premenopausal 
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women with DOR. Our observations identify DOR as a distinct entity in the paradigm of 
reproductive senescence.
Keywords
Diminished ovarian reserve; Premenopause; Perimenopause; LH surge; E1c; Pdg; Luteal 
insufficiency
Introduction
The concept of “ovarian reserve” is a relatively recent appreciation within the continuum of 
reproductive aging, and alludes to the number of remaining oocytes in any premenopausal 
female at a given age.1,2 Although ovarian reserve assessment is routinely undertaken in the 
context of infertility workup, this concept remains relatively underappreciated in the primary 
care setting. Pre-menopausal women diagnosed with diminished ovarian reserve (DOR) are 
without clinical stigmata other than sub fertility., Indeed, covert biomarkers and suboptimal 
quantitative and qualitative responses to attempts at ovarian stimulation during fertility 
treatment are the hallmarks of DOR in otherwise asymptomatic women.3 Despite strides in 
infertility management over recent years, suboptimal reproductive successes are recognized 
in patients with DOR.4–7
Recent studies have demonstrated an increased likelihood of early menopause in infertile 
women manifesting features of DOR,8–10 suggesting an acceleration of the process of 
reproductive aging in at least a subset of these young women.11 In a study of reproductive 
hormones in daily morning urine specimens collected over a spontaneous menstrual cycle, 
we had previously observed that the urinary reproductive hormone profiles in young women 
with DOR are distinct from those in age comparable controls.9 Significantly prolonged 
gonadotropin (FSH and LH) surges and significantly attenuated luteal excretion of estrogen 
and progesterone metabolites were noted in women with DOR compared to age comparable 
controls.9 Hypothesizing that DOR reflects accelerated reproductive aging, we herein 
compare urinary reproductive hormone dynamics between young women with DOR and a 
sample of chronologically older controls. Our analyses identify the reproductive hormone 
milieu of DOR as being distinct from that of chronologically advanced perimenopause.
Methods
Participants identified with DOR collected daily first morning voided urine over an entire 
menstrual cycle, as was previously described.9 The study was approved by the Institutional 
Review Board (IRB) at the Albert Einstein College of Medicine and Montefiore Medical 
Center. Daily morning urine samples were available from a historical cohort of 
perimenopausal controls, also was previously described.10 Of note, informed consent was 
available for all controls for use of data in future studies.
DOR Cases
Daily urinary reproductive hormone data were available for eight healthy, regularly cycling 
(21–35 days) infertile patients (age range 32–37 years).9 DOR was diagnosed by 1) early 
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follicular (Cycle Day 1–3) serum FSH concentration of greater than 10 mIU/ml (as per 
practice standard for the institution), and 2) suboptimal ovarian response to previous 
attempts at ovarian hyperstimulation (<3 dominant follicles after utilization of gonadotropins 
in excess of 300 U/day). Patients with abnormal serum level of prolactin, thyroid functions, 
or chronic diseases were excluded.
Perimenopausal Controls
Previously reported urinary reproductive hormone data10 for 11 healthy regularly cycling, 
perimenopausal normo-prolactinemic and euthyroid historic controls were utilized for 
comparison.
Specimen Collection
Details on specimen collection procedures have been published previously.9,10 Briefly, the 
participants were asked to collect first morning voided urine specimen in supplied containers 
and transfer a portion of the volume to the provided polypropylene tubes up to the specified 
mark; the tubes were prefilled with glycerol (final concentration of 7% glycerol was 
achieved in the collected urine sample).9,10 Glycerol-preserved specimens were used for all 
assays, because this has been reported to permit measurement of LH and FSH over long 
storage intervals and does not interfere with E1c or Pdg assay.11–14 The participants were 
instructed to store the tubes in a provided box within the home freezer. Specimens were 
transported to the laboratory at the end of the collection period and stored at −20°C.9,10 All 
subjects were provided with written instructions regarding the procedure of collection and 
storage of urine samples over an entire menstrual cycle (first day of menses to the first day 
of next menstrual flow).
Hormone Assays
Urinary LH and FSH were measured using a solid-phase, two-site specific fluoro-
immunometric assay (DELFIA; Perkin Elmer, Turku, Finland) and were validated in our 
laboratory using previously described methods.9,10,14 For the urinary LH, inter-assay 
coefficient of variation (CV) and intra-assay CV’s were 13.7 and 5.0%, respectively, and 
16.4 and 7.6% for FSH, respectively. E1c and Pdg were measured in duplicate by ELISA 
using antibodies and conjugate tracers provided by Dr. Bill Lasley (University of California, 
Davis, CA).14,15 The inter-assay CV for E1c was 10.1% and the intra-assay CV was 8.4%. 
Corresponding CVs for Pdg were 15.0 and 14.0% respectively. Urinary hormone 
concentrations were adjusted for glycerol and normalized to urinary creatinine (Cr).16 A 
portion of the historical samples of the control group were assayed concurrently with those 
from the experimental group, as a quality control measure to assure against assay drift on the 
available stored control samples. Cycles were centralized to the day of the LH surge (Day 
Zero), which was defined using established statistical methods.10 Presence of luteal activity 
was determined by a sustained increase in Pdg concentrations of ≥3µg/mgCr for 3 
consecutive days. Days −14 to −1 (inclusive) identified the follicular phase, whereas days 
−14 to −6, excluding day −6, defined the early follicular phase. Luteal phase was defined as 
days +2 to +14 (inclusive). Luteal phase adequacy was defined as any day on which urinary 
Pdg exceeded 3µg/mgCr.9
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Data Analyses
Data were organized into Microsoft Excel spreadsheets and inspected for error and 
completeness. The duration of LH and FSH surges was defined as the number of days of 
persistent elevation in the respective gonadotropin levels above a threshold of a 3-standard 
deviations (SD) increase from a follicular phase nadir baseline, which was calculated using a 
5-day moving average.17 The integrated urinary excretion of the individual urinary 
hormones was evaluated for participants with DOR and the healthy perimenopausal controls. 
Hormone levels for the early follicular as well as the entire follicular and luteal phases, and 
for the LH and FSH surges in the two groups were compared by. The levels of E1c on day 
−1, i.e. the day prior to LH surge, the duration of LH and FSH surge (in days) and the 
duration of adequacy of luteal phase were similarly assessed in the two groups. Area-under-
the-curve (AUC) analyses were calculated using Prism 4.0 (GraphPad Software, La Jolla, 
CA) for comparison. All comparisons were made using non parametric Mann- Whitney U 
test due to a non-Gaussian distribution of the hormone data. SPSS 16.0 (SPSS Inc, Chicago, 
IL.) was used for analyses and P < 0.05 was considered as statistically significant.
Results
Data presented reflect the urinary hormone profile over a single menstrual cycle in 8 
premenopausal women with DOR (age range 32–37 years) and 11 perimenopausal historical 
controls (age range 43–52 years). One patient with DOR failed to provide urine samples 
beyond cycle day #16 (2 days after LH surge), and thus was excluded from analysis 
evaluating the duration of LH and FSH surges and luteal Pdg levels. All participants 
displayed adequate FSH and LH surges. All perimenopausal controls and 7 of the DOR 
patients exhibited luteal activity as reflected by predefined urinary Pdg excursions 
(excluding the one DOR case who failed to provide post-LH surge urine samples).
Although early follicular phase FSH level of >10mIU/ml was a diagnostic criterion for DOR 
(as specified in methods section), the early follicular urinary FSH levels were significantly 
lower in the DOR group compared to the older perimenopausal population (p < 0.001, 
Figure 1). The mid cycle urinary FSH surge was comparable in the two groups, both in 
amplitude and in duration (Table 1). The LH surge, however, were significantly exaggerated 
in the DOR, in both amplitude and in duration, compared to the older perimenopausal cohort 
(Table 1, Figure 2).
As is demonstrated in Figure 3 and Table 1, significantly attenuated urinary E1c levels, both 
in the follicular and the luteal phases of the cycle, were observed in the DOR group 
compared to the perimenopausal older controls. The pre-surge E1c level was lower in 
premenopausal women with DOR compared to the older perimenopausal group and this 
difference approached statistical significance (p = 0.062). Although, the luteal urinary Pdg 
levels were lower and the duration of luteal phase adequacy shorter in young women with 
DOR compared to the older perimenopausal controls, these differences were not statistically 
significant (Table 1, Figure 4).
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Discussion
We had previously described distinctions in the reproductive hormone milieu of infertile 
women with DOR compared to healthy reproductive age controls with normal ovarian 
reserve.9 Our current study extends our earlier observations and identifies distinctions 
between DOR and chronologically advanced perimenopause. DOR is thus appreciated as a 
distinct entity in the paradigm of reproductive aging. Elevation in FSH is a recognized 
hallmark of reproductive aging18–20 and is appreciated concomitantly with declining ovarian 
reserve. Gonadal signals such as inhibin, activin and follistatin are recognized modulators of 
FSH secretion.21–23 In this context, the blunted elevation in follicular phase urinary FSH in 
premenopausal women with DOR compared to the older perimenopausal controls may 
reflect a higher level of counter-regulatory gonadal hormones, e.g., inhibin, activin, and 
follistatin, and hence a relatively replete ovarian reserve in the younger population compared 
to the older perimenopausal cohort. This is consistent with the fact that the women with 
DOR were still cycling regularly, while the perimenopausal controls had experienced some 
cycle irregularity10 (i.e., at least one skipped menstrual period within the 3 months prior to 
enrollment).
The significantly higher urinary E1c level in the chronologically older perimenopausal 
cohort was previously reported, and identifies the perimenopause as a state of relative 
estrogen excess.10,24–28 Conversely, these comparative analyses suggest premenopausal 
DOR as a state of relative hypoestrogenism compared to the more advanced stage of 
reproductive aging, i.e. perimenopause. Indeed, we have previously identified DOR as a risk 
for premenopausal bone loss and low bone mass8 and have suggested relative 
hypoestrogenism as a pathophysiological mechanism in this regard.
Our findings of significantly more prominent LH surges in the setting of DOR, compared to 
perimenopause, especially in the light of the observed blunted E1c excretion observed in the 
former, was unexpected. In contrast to the previously reported failure to elicit an LH surge 
despite normal estrogen exposure in some perimenopausal women,29 we observed an 
exaggerated and protracted urinary LH surge in premenopausal women with DOR in the 
setting of relative hypoestrogenism. Indeed, a dampening of the positive hypothalamic-
pituitary feedback response to estrogen is recognized as a feature of the menopausal 
transition. However, premenopausal women with DOR displayed robust gonadotropin 
surges, suggesting an enhanced hypothalamic-pituitary sensitivity to the relatively 
hypoestrogenic milieu. Thus, women with DOR appear to have hormonal feedback 
responses that are distinct from both the healthy young women with normal ovarian 
reserve9, as well as from a chronologically older cohort of perimenopausal women. The 
observed differences in the reproductive hormone dynamics between premenopausal women 
with DOR and the older perimenopausal controls may be attributable, in part, to the residual 
ovarian reserve in the former, as reflected by regular menstrual cyclicity in all women 
diagnosed with DOR. Regularly menstruating premenopausal women with DOR may thus 
be earlier in the process of progressive ovarian senescence compared to the older 
perimenopausal cohort. Alternatively, chronological differences between the two groups 
may underlie the observed differences.
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Our finding of a protracted LH surge in premenopausal women with DOR is novel and not 
previously reported. An extensive search of published English literature on Medline and 
Pubmed from years 1990 to 2010 using search terms “protracted LH surge”, “prolonged LH 
surge”, “LH surge duration”, and “duration of LH surge” yielded no similar finding in either 
human or animal studies. Fowler and colleagues suggested that the ovarian gonadotropin 
surge attenuating factor (GnSAF) play a role in the negative regulation of pulsatile LH 
secretion.30 A decline in GnSAF was previously reported in both poor responders to ovarian 
stimulation and in aging women,31 and hence may not be the unifying mediator for the 
observed differences in our data. GnRH pulses were known to stimulate the synthesis and 
secretion of LH and FSH from the anterior pituitary. Rapid GnRH pulse frequencies of more 
than one pulse per hour favor LH secretion while slow pulse frequencies of less than one 
pulse in 2 to 3 hours favor FSH secretion.32 A recent study by Christian and colleagues on 
ovariectomized mice suggested the switch of estrogen negative feedback to positive 
feedback in LH surge initiation is related to the pattern and level of individual GnRH neuron 
firing.33 Dysregulation of GnRH pulsatility, or a failure of down regulation in the number 
and function of the available GnRH receptors in the gonadotropes, or a failure to terminate 
the GnRH positive feedback may be theorized as additional plausible mechanisms 
contributing to the observed protracted LH surge in premenopausal women with DOR. An 
examination of the minute-to-minute characteristics of pulsatile GnRH/LH secretion in 
women with DOR may be helpful in elucidating the underlying pathophysiology.
The overall urinary E1c excretion was observed to be significantly lower in premenopausal 
women with DOR compared to the perimenopausal cohort. The magnitude of this 
differential in urinary E1c excretion in the two groups is likely influenced in part by the 
relative estrogen excess of perimenopause,10,24–28 and by the relative hypoestrogenism of 
DOR.9 Urinary E1c levels are recognized to reliably reflect ovarian estrogen production, as 
reflected by paired analyses of urine and serum samples.34 A difference in estrogen 
metabolic rates between the two groups is additionally plausible and may theoretically be 
contributory to the observed group differences in urinary E1c levels, a conjecture that cannot 
be elaborated upon, given the constraints of our study design. Serum estrogen levels are 
recognized to relate to body mass, particularly in postmenopausal women.35 While 
differences in body mass may be theorized to influence estrogen metabolites, urinary E1c 
levels are recognized to reflect ovarian rather than peripheral estrogens34 and are unlikely to 
be influenced by body mass index, as has previously been described.36
Luteal insufficiency is recognized as contributory to the reproductive compromise of 
aging37, and we have previously demonstrated evidence of luteal inefficiency in the context 
of DOR.9 The observed luteal Pdg profiles suggest comparable degrees of luteal 
compromise in the setting of premature (i.e. DOR) and age appropriate (i.e. perimenopause) 
ovarian senescence. Although the underlying pathophysiological mechanisms remain far 
from clear, based on these observations, one may hypothesize that inadequate luteal 
progesterone secretion may be a common denominator to the reproductive compromise of 
aging and that seen in the context of compromised ovarian reserve9, 34, a conjecture that 
merits substantiation by future studies.
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The small sample size of our study is an obvious limitation that is a likely contributory to the 
relatively large standard errors observed in some measurements, such as of LH. This small 
sample highlights recruitment constraints that are appreciable in studies of infertile women 
with DOR, an emotionally fragile population that is reluctant to defer pursuit of fertility 
attempts in favor of participation in clinical research.38 Although historic perimeopausal 
controls were used, stored urinary samples were tested using established methods39–40 to 
ensure stability of hormone levels and consistency in assays. FSH receptor polymorphism is 
a recognized pathophysiologic mechanism for compromised ovarian reserve, albeit only in a 
subset of DOR population.41 This information unfortunately is not available for the studied 
cohort. Finally, an observational study such as this precludes the establishment of any cause-
effect relationship; these observations however offer meaningful direction for future studies.
Conclusion
Our data indicate distinct reproductive hormone dynamics in young infertile women with 
DOR compared to older perimenopausal women. Distinctions (significantly lower E1c in 
addition to higher amplitude and duration of LH surge evident in premenopausal women 
with DOR compared to the perimenopausal cohort) as well as similarities (comparable luteal 
Pdg urinary excretion in the two groups) are identified in the urinary reproductive hormone 
profiles of the two population samples. Further investigations are needed to better appreciate 
and help disentangle the mechanisms that may underlie the observed differences in the 
reproductive hormone milieu, and better elucidate a place for premenopausal DOR in the 
paradigm of reproductive aging.
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FIG. 1. 
Daily profile of urinary FSH levels across an entire menstrual cycle in 8 premenopausal 
women with DOR and 11 older perimenopausal controls. Compared with the older controls, 
the DOR cases demonstrate significantly lower FSH levels in the early follicular phase (P < 
0.001). The amplitude and duration of the FSH surge are comparable in the two groups. 
Note: centering of cycles relative to the LH surge (day 0). FSH, follicle-stimulating 
hormone; DOR, diminished ovarian reserve; LH, luteinizing hormone.
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FIG. 2. 
Daily profile of urinary LH levels across an entire menstrual cycle in 8 premenopausal 
women with DOR and 11 older perimenopausal controls. An exaggerated urinary LH surge 
is observed in premenopausal women with DOR compared with the older perimenopausal 
controls; the duration and amplitude of the LH surge are significantly different between the 
two groups (P < 0.001). Note: centering of cycles relative to the LH surge (day 0). LH, 
luteinizing hormone; DOR, diminished ovarian reserve.
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FIG. 3. 
Profile of daily urinary E1c excretion across a spontaneous menstrual cycle suggests relative 
hypoestrogenism in premenopausal women with DOR (n = 8) compared with the older 
perimenopausal controls (n = 11). The differences in urinary E1c levels in the two groups 
are of statistical significance across the different phases of the menstrual cycle (see Table 1 
for details). Note: centering of cycles relative to the LH surge (day 0). E1c, estrogen 
conjugate; LH, luteinizing hormone; DOR, diminished ovarian reserve.
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FIG. 4. 
Comparable urinary levels of progesterone metabolite Pdg are observed in premenopausal 
women with DOR (n = 8) and older perimenopausal controls (n = 11; P > 0.05). Note: 
centering of cycles relative to the LH surge (day 0). Pdg, progesterone; LH, luteinizing 
hormone; DOR, diminished ovarian reserve.
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Table
Summary of hormonal characteristics in 8 premenopausal women with diminished ovarian reserve (DOR) and 
11 healthy perimenopausal controls (mean ± SEM)
DOR Perimenopausal p-value
FSH
  Early follicular phase (mU/mgCr) 7.48 ± 0.66 26.28 ± 3.0 < 0.001
  Duration of surge (days) 2.38 ± 0.32 1.64 ± 0.31 0.066
  Magnitude of surge (mU/mgCr) 26.15 ± 9.45 35.39 ± 4.93 0.069
LH
  Duration of surge (days) 3.25 ± 0.45 1.45 ± 0.16 < 0.001
  Magnitude of surge (mU/mgCr) 63.91 ± 16.0 31.1 ± 8.43 0.048
E1c
  Pre-surge peak (ng/mgCr) 56.54 ± 10.06 106.38 ± 16.71 0.062
  Follicular phase (ng/mgCr) 25.17 ± 2.07 53.11 ± 5.47 < 0.001
  Luteal phase (ng/mgCr)† 31.9 ± 2.07 81.07 ± 5.98 < 0.001
  Whole cycle AUC (ng/mgCr)† 654 ± 104 1625 ± 324 0.041
Pdg
  AUC (µg/mgCr)† 54.85 ± 11.46 77.21 ± 13.08 0.272
  Luteal adequacy†§ 7.29 ± 1.34 9.7 ± 0.96 0.070
†One patient with DOR failed to provide luteal phase urine samples, and thus, her data was excluded from the analyses.
§
Luteal adequacy was defined as a Pdg level of greater than 3µg/mgCr.
Menopause. Author manuscript; available in PMC 2018 February 17.
